
KPV
KPV is a three-amino-acid fragment of the hormone alpha-MSH. In mice it reduced experimental colitis when added to drinking water, and in lab tests it calmed inflammatory signals. It has never been tested in a published human study by any route, and FDA found no human exposure data, no toxicity studies in animals and no adverse event reports. A draft HHS policy from October 2026 says HHS does not intend to take enforcement action against compounding of topical and oral KPV acetate by licensed parties under listed conditions, which is not an approval.
Research compound: not an approved drug or dietary supplement
This compound is sold for research and is not FDA-approved for human use or as a dietary supplement. Human evidence is limited; purity and dosing of consumer products are unverified. The data below is an evidence review for education only. Talk to a clinician before considering it.
Quick decision guide
May help most
No approved or proven use
Common dosing range
No approved or established dose. KPV has never been given to people in a published study
When to expect effects
Not established in people
Watch out for
Not FDA-approved; FDA found no human exposure data by any route and no animal toxicity studies, so its safety in people is unknown; online and "research use only" products are unverified
What is it
KPV is a lab-made tripeptide: three amino acids, lysine, proline and valine (Lys-Pro-Val). It copies the last three amino acids (positions 11 to 13) of alpha-melanocyte stimulating hormone (alpha-MSH), a natural hormone with anti-inflammatory effects. FDA found it promoted online as injections, oral products, creams and nasal sprays for gut inflammation, skin conditions and wound healing. It is not FDA-approved for any use, it is not a component of any approved drug, and FDA's 2026 review found no published study in which KPV was given to people by any route. FDA's compounding safety page lists KPV among bulk substances previously in category 2 (may present significant safety risks) whose nominations were withdrawn, and says FDA has not identified any human exposure data and lacks important information on whether it would cause harm (content current as of April 22, 2026). In its briefing document for the July 23-24, 2026 meeting of its Pharmacy Compounding Advisory Committee, FDA wrote that "we propose not adding" KPV to the list of bulk substances pharmacies may use in compounding. On October 30, 2026, the Department of Health and Human Services (the Secretary's office, not FDA) published a DRAFT enforcement discretion policy (91 FR 68526) that lists KPV in its Appendix A: HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician compounding a drug with it under listed conditions; the policy document limits KPV acetate to topical and oral forms. The notice says the draft "does not establish any rights for any person and is not binding on HHS or the public", and HHS may revisit it. It is not an FDA approval, and it applies only to compounding by those licensed parties, not to "research use only" products sold online.
Is it worth it for you?
Use this as a quick fit check, not a diagnosis.
Worth considering if…
Probably skip if…
Evidence at a glance
| Goal | Effect | Best fit | Time |
|---|---|---|---|
experimental colitis in mice Mixed Evidence | Less colon inflammation and faster weight recovery than untreated mice | None in people | Days in mice |
experimental colitis in mice
- Effect
- Less colon inflammation and faster weight recovery than untreated mice
- Best fit
- None in people
- Time
- Days in mice
Evidence for 1 use
AI-assisted evidence assessment. Talk to your doctor before relying on any single supplement.
experimental colitis in mice
Mechanism onlyIn mice with chemically induced colitis (DSS and TNBS models), KPV added to the drinking water reduced inflammation and inflammatory cytokine levels, and in cell studies nanomolar amounts blocked NF-kappaB and MAP kinase signaling after entering cells through the PepT1 transporter. A second group found that KPV-treated mice with DSS colitis or T-cell transfer colitis recovered body weight sooner and had less inflammation in the colon, and in mice lacking a working melanocortin-1 receptor, KPV treatment prevented death from DSS colitis in all treated animals, suggesting it works at least partly without that receptor. These are mouse results and have never been tested in people: FDA's 2026 review found no human study of KPV by any route.
Bottom line: KPV reduced colitis in mice, but it has never been tested in people.
How it works
How to take it
What to track
Bottom line: No human dose has ever been tested; products sold today are untested in people.
Safety
Know the common side effects, key cautions, and who should avoid it.
Common side effects
Serious risks
No human safety data. FDA found no clinical studies or human exposure data for KPV by any route, no reports in its adverse event database or its food and supplement complaint system through December 3, 2025, and no published case reports, and concluded that potential safety risks in humans are unknown.
No toxicity studies. FDA found no pharmacokinetic, acute, repeat-dose, genetic, reproductive or cancer toxicity studies of KPV in animals.
Immune reactions and quality. FDA notes that even very short peptides can clump (aggregate), which can raise the risk of immune reactions, and that no study has assessed this for KPV.
Unverified products and combinations. FDA found KPV promoted as injections, oral products, creams and nasal sprays, and in combination products with BPC-157, TB-500, AOD-9604 and follistatin-344. FDA found no published study in which a drug product containing KPV was used in people. The October 2026 draft HHS policy covers only compounding of topical and oral KPV acetate by a state-licensed pharmacy, federal facility or licensed physician under listed conditions.
Who should avoid it
- Anyone outside a supervised clinical trial: FDA has not identified any human exposure data for KPV
- People with inflammatory bowel disease, psoriasis, eczema or chronic wounds who might use it instead of proven treatment: FDA notes these can be serious conditions with approved, effective therapies
Pregnancy & breastfeeding
There are no human data on KPV in pregnancy or breastfeeding, and FDA found no animal studies of its effects on reproduction or development. Avoid use if you are pregnant, breastfeeding or planning a pregnancy, and talk to your doctor.
Choosing a product
What to look for on the label, and what to be skeptical of.
Look for…
Be skeptical of…
Frequently asked questions
Is KPV FDA-approved?⌄
No. No KPV product is approved by FDA, and FDA's 2026 review found no authorized product in the European Union. FDA's compounding safety page lists it among substances previously in category 2 (may present significant safety risks) whose nominations were withdrawn.
What did HHS announce about KPV in October 2026?⌄
On October 30, 2026, HHS published a draft enforcement discretion policy (91 FR 68526) that lists KPV with five other peptides. HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician compounding a drug with KPV for an individual patient with a valid prescription, if conditions are met, such as an FDA-registered manufacturer, a certificate of analysis, a single active ingredient and reporting of serious adverse events. The policy document limits KPV acetate to topical and oral forms, so it does not cover injections or nasal sprays. The notice says the draft "does not establish any rights for any person and is not binding on HHS or the public", and HHS may revisit it. It is not an FDA approval.
Has KPV been tested in people?⌄
No. FDA's 2026 review found no published study in which KPV was given to people by any route, and no clinical trial of KPV was listed on ClinicalTrials.gov on November 19, 2026. The evidence comes from mouse colitis models and cell studies.
Is KPV the same as melanotan or a tanning peptide?⌄
No. KPV is a different peptide, a three-amino-acid piece of the hormone alpha-MSH; FDA lists melanotan II as a separate substance on its compounding safety page. In lab studies KPV did not displace alpha-MSH from melanocortin receptors, including in cells carrying the skin pigment receptor (MC1), and FDA's review notes these receptors are unlikely to explain its effects.
Can I take KPV with my supplements or medicines?⌄
No interaction studies exist, and KPV has never been studied in people. If you take medicines for inflammatory bowel disease or a skin condition, talk to your doctor before making any change. Ask a doctor or pharmacist to review your full list.
References by claim
experimental colitis in mice
Safety
FDA briefing document for the July 23-24, 2026 Pharmacy Compounding Advisory Committee: KPV-related bulk drug substances · FDA link
FDA: Certain bulk drug substances for use in compounding that may present significant safety risks · FDA link
Federal Register, October 30, 2026 (91 FR 68526): Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · HHS link
Track KPV with Pilora
Set up dose reminders, check interactions, and join the community in the Pilora app.
Disclaimer: This compound is not approved by the FDA for human use and is not a dietary supplement. This page is an educational review of available research (much of it preclinical or early-stage), not a recommendation to use it. Consumer product quality is unregulated. Consult a qualified clinician.
